FDA’s TERSELIC RETIRING ON SEPT. 3
FDA's TERSELIC RETIRING ON SEPT. 3 after more than 23 years with the agency. Richard Terselic, 56, has held the position of assistant to Center for Drug Evaluation and Research Deputy Director Gerald Meyer since October 1990. Upon his retirement, Terselic says he plans to devote more time to his 13-year-old, family-owned hubcap business in Rockville, Md. As Meyer's assistant, Terselic has directed a number of special projects, including assessment of the chemistry review process and research into the drug master file system. These special projects have resulted in a number of recommendations that are being implemented at the center, including exploration of computerizing DMFs. Terselic also advises Meyer on policy proposals and strategies. Terselic joined FDA in 1970 as assistant director for planning and analysis in the then-Bureau of Drugs. In 1982, he became deputy director for program management in the Office of Drug Evaluation I. From December 1975 to January 1977, Terselic was detailed to the Office of Technology Assessment to conduct a study on means of improving the safe, effective and economical use of drugs. From May 1989 to October 1990, during the upheaval caused by the generic drug scandal, Terselic served as acting director of the Division of Generic Drugs. One of his accomplishments in strengthening the division was the creation of written policy and procedure guides. He received several FDA awards including the Award of Merit in 1991 and the Commendable Service Award in 1981. Before joining FDA, Terselic worked at the National Cancer Institute as a systems analyst involved in developing viral oncology and cancer chemotherapy research program designs. Prior to NCI, he held positions at the Department of Commerce and NASA.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Sign in to continue reading.
Need a specific report?
1000+ reports available
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: